Experimental therapy targets protein clumps behind Parkinson's disease

Scientists have developed an experimental molecule that may help tackle the underlying cause of Parkinson's disease by preventing the formation of toxic protein clumps, offering a potential new approach to treating the neurodegenerative disorder rather than simply managing its symptoms.

Current therapies for Parkinson's disease and related conditions primarily relieve symptoms but do not halt the biological processes that drive the disease. The new study received coverage in an article published by The Conversation outlet, which notes that the scientific work focuses on preventing the accumulation of alpha-synuclein, a protein that is widely believed to play a central role in the development and progression of Parkinson's.

The experimental molecule, known as SK-129, acts like a molecular brace by binding to several regions of alpha-synuclein and stabilizing it in a shape that makes it less likely to stick to other protein molecules.

Researchers found that SK-129 binds particularly strongly to the early forms of toxic protein aggregates, preventing them from growing and forming additional clumps.

The study also explored the broader therapeutic potential of foldamers, the class of synthetic molecules to which SK-129 belongs.

Foldamers are laboratory-designed molecules that fold into predictable three-dimensional structures, similar to natural proteins. Their stability allows scientists to engineer them to recognize and bind to specific biological targets with high precision.

According to the researchers, this versatility could prove especially valuable because many proteins associated with neurodegenerative diseases have long been considered "undruggable."

Unlike proteins targeted by many conventional medicines, alpha-synuclein and similar disease-related proteins are highly flexible and lack well-defined binding pockets where drugs can attach.

Synthetic foldamers provide larger binding surfaces that can interact with these difficult targets, disrupting the abnormal protein interactions responsible for toxic aggregation.

The researchers believe this approach could eventually lead to new treatments not only for Parkinson's disease but also for other neurodegenerative disorders driven by toxic protein buildup, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

While SK-129 demonstrated strong potential in laboratory and animal studies, the researchers cautioned that it has not yet been tested in humans.

Key questions remain regarding the molecule's long-term safety, optimal dosage, and how it is absorbed, distributed and processed by the human body. Further studies will be needed to better understand its mechanism of action and determine whether it can safely slow or prevent the progression of Parkinson's disease in patients.

Other therapies under development

SK-129 is one of several experimental approaches being investigated to target the toxic alpha-synuclein aggregates associated with Parkinson's disease and related neurological disorders.

Researchers are also developing therapies designed to remove these protein clumps, reduce the production of alpha-synuclein, or prevent the proteins from aggregating in the first place.

Several of these experimental strategies have already progressed into clinical trials, reflecting growing efforts to develop disease-modifying treatments that address the root causes of Parkinson's rather than its symptoms alone.

By Nazrin Sadigova